GLP-1 and Dual Incretin Peptide Drugs Are Displacing Insulin as the Go-To Treatment for Type 2 Diabetes
GLP-1 receptor agonists and dual incretin peptide drugs are increasingly prioritized over basal insulin for type 2 diabetes, though insulin remains essential for patients with advanced beta-cell failure.
Quick Facts
What This Study Found
GLP-1 receptor agonists and dual incretin agonists (like tirzepatide) are increasingly prioritized over basal insulin for type 2 diabetes due to superior efficacy, cardiovascular benefits, weight loss, and safety. However, basal insulin remains indispensable for patients with advanced beta-cell failure, severe hyperglycemia, or contraindications to newer agents. The review advocates personalized, pathophysiology-driven therapy selection including integration of new once-weekly insulin formulations.
Key Numbers
GLP-1 RAs, SGLT2 inhibitors, dual incretin agonists vs basal insulin · once-weekly insulin formulations · personalized therapy selection
How They Did This
Expert review article with targeted PubMed literature search focusing on cardiovascular outcomes trials, head-to-head comparison studies, and major diabetes treatment guidelines comparing newer agents (GLP-1 RAs, SGLT2i, dual incretins) to basal insulin.
Why This Research Matters
The diabetes treatment hierarchy is rapidly being rewritten by peptide-based incretin drugs. This review captures a pivotal moment: GLP-1 agonists and dual incretins are displacing insulin from its decades-long position as the default treatment intensification option, fundamentally changing how type 2 diabetes is managed.
The Bigger Picture
This review reflects a seismic shift in diabetes care driven by peptide drug innovation. GLP-1 receptor agonists and dual GLP-1/GIP agonists have moved from niche options to first-line contenders, fundamentally challenging insulin's 100-year reign. The emergence of once-weekly insulin (icodec) and insulin-semaglutide combinations (IcoSema) suggests the future may involve integrated peptide-insulin products rather than an either/or choice.
What This Study Doesn't Tell Us
Expert opinion/editorial format rather than systematic review. Brief article (4 pages). Does not quantify specific outcome differences between drug classes. May not capture the full breadth of patient scenarios. Does not address cost-effectiveness or global access disparities.
Questions This Raises
- ?Will basal insulin eventually be reserved only for late-stage type 2 diabetes, or will new formulations keep it competitive?
- ?How should clinicians decide between GLP-1 monotherapy, dual incretins, and insulin-peptide combinations?
- ?Will cost and access barriers limit the shift away from insulin in lower-income healthcare settings?
Trust & Context
- Key Stat:
- Insulin role narrowing GLP-1 RAs and dual incretins are displacing basal insulin as first-line intensification due to superior weight, cardiovascular, and safety profiles
- Evidence Grade:
- This is an expert review article synthesizing evidence from major trials and guidelines, published in a specialist endocrinology journal. It provides clinical context and recommendations but is not a systematic review or meta-analysis.
- Study Age:
- Published in 2025, this captures the current state of the rapidly evolving diabetes treatment landscape, including the impact of tirzepatide and once-weekly insulin formulations.
- Original Title:
- Basal insulin in the age of innovation: are diamonds still forever?
- Published In:
- Expert review of endocrinology & metabolism, 20(6), 471-474 (2025)
- Authors:
- Koufakis, Theocharis(8), Patoulias, Dimitrios(10), Popovic, Djordje S(7), Tsimihodimos, Vasileios
- Database ID:
- RPEP-11908
Evidence Hierarchy
Frequently Asked Questions
Why are GLP-1 drugs now preferred over insulin for type 2 diabetes?
GLP-1 receptor agonists offer three things insulin can't: they help patients lose weight (insulin causes weight gain), they protect the heart (proven in large trials), and they rarely cause dangerous low blood sugar. Combined with comparable blood sugar control, these advantages have made them the preferred first-line intensification for most patients.
When is insulin still the right choice?
Insulin remains essential when the pancreas has largely stopped making its own insulin (advanced beta-cell failure), when blood sugar is dangerously high and needs rapid control, or when patients can't use newer drugs due to side effects, cost, or other medical reasons. Even then, combining insulin with GLP-1 drugs may offer the best of both worlds.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11908APA
Koufakis, Theocharis; Patoulias, Dimitrios; Popovic, Djordje S; Tsimihodimos, Vasileios. (2025). Basal insulin in the age of innovation: are diamonds still forever?. Expert review of endocrinology & metabolism, 20(6), 471-474. https://doi.org/10.1080/17446651.2025.2580629
MLA
Koufakis, Theocharis, et al. "Basal insulin in the age of innovation: are diamonds still forever?." Expert review of endocrinology & metabolism, 2025. https://doi.org/10.1080/17446651.2025.2580629
RethinkPeptides
RethinkPeptides Research Database. "Basal insulin in the age of innovation: are diamonds still f..." RPEP-11908. Retrieved from https://rethinkpeptides.com/research/koufakis-2025-basal-insulin-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.